Diquafosol may benefit DED patients


Diquafosol may have a role in the management of dry eye disease (DED), according to a recently published review.

Diquafosol may have a role in the management of dry eye disease (DED), according to a recent review published in Clinical Ophthalmology.

Diquafosol is a uridine nucleotide analogue that is also a P2Y2 receptor agonist. Several randomized controlled trials have shown that the application of topical diquafosol significantly improves the objective markers of DED, including corneal and conjunctival fluorescein staining, tear film break-up time, and Schirmer's test scores. These improvements, however, are accompanied by only partial improvements in patient symptoms.

Both animal and human studies have shown that native P2Y2 agonists may be released at the ocular surface in response to trauma, and also shown to have numerous effects including increased mucin secretion, decreased fluorescein penetrance, accelerated wound healing, and the opening of chloride channels in the apical membrane.

"Progress in the understanding of dry eye pathophysiology and advances in diagnostic methods will help us better understand the place of diquafosol in the overall picture of DED management, overcome the discrepancy between signs and symptoms and find new markers to gauge efficacy in future clinical trials," wrote lead author Oliver C.F. Lau, Sydney Eye Hospital, Sydney, NSW, Australia, and co-authors.

"Further studies may be useful to clarify its role in specific subgroups of DED, such as meibomian gland dysfunction, Sjögren's syndrome, or DED recalcitrant to more traditional therapies. Longer-duration studies, as well as studies examining the effect of diquafosol on corneal sensation and nerve structure, and potential synergistic interplay between diquafosol and other therapeutic agents such as ocular lubri¬cants, traditional topical immunomodulatory agents such as prednisolone and cyclosporine, and newer targeted molecular agents would also be of great interest," the authors concluded.

To view the abstract, click here.

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Related Content
© 2023 MJH Life Sciences

All rights reserved.